Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2017 | Pages:
64 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Fibromyalgia - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibromyalgia - Pipeline Review, H2 2017, provides an overview of the Fibromyalgia (Central Nervous System) pipeline landscape. Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Symptoms include fatigue, depression, headaches, and pain or cramping in the lower abdomen. The predisposing factors include family history, rheumatoid arthritis or lupus. Treatment includes pain relievers, antidepressants and anti-seizure drugs. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibromyalgia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Fibromyalgia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Fibromyalgia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Fibromyalgia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 5, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively. Fibromyalgia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Fibromyalgia (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Fibromyalgia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Fibromyalgia (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Fibromyalgia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Fibromyalgia (Central Nervous System) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Fibromyalgia (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Fibromyalgia (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Fibromyalgia - Overview Fibromyalgia - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Fibromyalgia - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Fibromyalgia - Companies Involved in Therapeutics Development Astellas Pharma Inc Daiichi Sankyo Company Ltd Immune Therapeutics Inc Innovative Med Concepts LLC Intec Pharma ltd Jiangsu Hengrui Medicine Co Ltd KPI Therapeutics Inc Merck & Co Inc Pfizer Inc Switch Biotech LLC Zynerba Pharmaceuticals Inc Fibromyalgia - Drug Profiles (cannabidiol + dronabinol) - Drug Profile Product Description Mechanism Of Action R&D Progress (celecoxib + famciclovir) - Drug Profile Product Description Mechanism Of Action R&D Progress AS-1069562 - Drug Profile Product Description Mechanism Of Action R&D Progress ASP-0819 - Drug Profile Product Description Mechanism Of Action R&D Progress ASP-8062 - Drug Profile Product Description Mechanism Of Action R&D Progress mirogabalin besylate - Drug Profile Product Description Mechanism Of Action R&D Progress mirtazapine ODT - Drug Profile Product Description Mechanism Of Action R&D Progress naltrexone hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress Peptide to Block Voltage-Dependent N-Type Calcium Channel for Central Nervous System - Drug Profile Product Description Mechanism Of Action R&D Progress pregabalin CR - Drug Profile Product Description Mechanism Of Action R&D Progress pregabalin SR - Drug Profile Product Description Mechanism Of Action R&D Progress SWT-06101 - Drug Profile Product Description Mechanism Of Action R&D Progress U-2902 - Drug Profile Product Description Mechanism Of Action R&D Progress ZYN-001 - Drug Profile Product Description Mechanism Of Action R&D Progress Fibromyalgia - Dormant Projects Fibromyalgia - Discontinued Products Fibromyalgia - Product Development Milestones Featured News & Press Releases Jun 30, 2017: Daiichi Sankyo Announces Top-line Results from Phase 3 Global Clinical Development Program Evaluating Mirogabalin in Pain Syndromes Jun 26, 2017: Zynerba Pharmaceuticals Initiates ZYN001 Phase 1 Clinical Program Mar 22, 2017: Intec Pharma Initiates Phase I Trial of Accordion Pill for Cannabinoid Therapies Mar 07, 2017: Journal of Pain Research Publishes Results of PRID-201, a successful Phase 2 Trial using IMC-1 for the Treatment of Fibromyalgia Oct 17, 2016: Zynerba Provides Clinical Update for Lead Development Candidate ZYN001 Jan 28, 2016: Innovative Med Concepts Announces Receipt of FDA Fast Track Designation for IMC-1, a Novel Treatment for Fibromyalgia Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin Nov 18, 2014: Novel Fibromyalgia Treatment Shows Promise In Study Nov 27, 2012: Intellipharmaceutics Announces Results Of Initial Phase I Clinical Trial Of Controlled-release Pregabalin Nov 19, 2012: Pfizer Reports Top-line Results Of Phase III Study Evaluating Pregabalin Controlled-release As Treatment For Patients With Fibromyalgia Jul 23, 2012: Pfizer Reports Top-Line Results Of EU Post-Authorization Safety And Efficacy Study Of Lyrica's Discontinuation Effects In Patients With Generalized Anxiety Disorder Feb 02, 2009: UCB Announces Top-Line Outcomes For Proof-Of-Concept Studies Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Fibromyalgia, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Fibromyalgia - Pipeline by Astellas Pharma Inc, H2 2017 Fibromyalgia - Pipeline by Daiichi Sankyo Company Ltd, H2 2017 Fibromyalgia - Pipeline by Immune Therapeutics Inc, H2 2017 Fibromyalgia - Pipeline by Innovative Med Concepts LLC, H2 2017 Fibromyalgia - Pipeline by Intec Pharma ltd, H2 2017 Fibromyalgia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017 Fibromyalgia - Pipeline by KPI Therapeutics Inc, H2 2017 Fibromyalgia - Pipeline by Merck & Co Inc, H2 2017 Fibromyalgia - Pipeline by Pfizer Inc, H2 2017 Fibromyalgia - Pipeline by Switch Biotech LLC, H2 2017 Fibromyalgia - Pipeline by Zynerba Pharmaceuticals Inc, H2 2017 Fibromyalgia - Dormant Projects, H2 2017 Fibromyalgia - Dormant Projects, H2 2017 (Contd..1), H2 2017 Fibromyalgia - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
